COMPARE · Data as of August 24, 2026
ABBV vs ANIP
Verdict: Side-by-side breakdown using the Bull Rankings model. ABBV scored 63.6, ANIP scored 80.0 — ANIP leads.
Compare another set
ABBV
AbbVie Inc.
63.6
$264.52 · $467.4B
fundamentals as of
Score gap
16.4
ANIP leads
ANIP
ANI Pharmaceuticals, Inc.
80
$74.17 · $1.7B
fundamentals as of
At a glance · who leads each dimension, on the model's own rules
- CheapestANIP16.2x
- Fastest growthANIP+30.9%
- Highest qualityABBV71 / 100
- Largest discount to fair valueANIP-47%
Side by side · every name on one set of axes
Growth against the P/E multiple. Up and to the right is cheaper and faster — the quality-growth idea in one picture. Points beyond the axis are pinned to the edge and marked off-scale rather than allowed to compress everything else.
The model, pillar by pillar (0–100 each)
ABBV
stronger →← stronger
ANIP
71
Qualityreturns · margins · balance sheet
66
66
Growthrevenue & earnings expansion
94
55
Valuevaluation vs sector peers
82
ANIP is stronger on 2 of 3 pillars.
Fundamentals, head-to-head
ABBV
ANIP
$18.2bA-
FCF
$173mC
+10.4%B
Rev
+30.9%A
—
D/E
1.05C
74.5xC
P/E
16.2xA-
0.43A
PEG
1.21B
Winner per row is the stronger grade; where grades tie, the better figure breaks it. A true tie or a missing value shows no highlight.
Valuation · DCF cross-check
ABBV
ANIP
31% above
Price vs fair valuelower is cheaper
47% below
~17%/yr
Growth the price implies10-yr FCF · lower = less priced in
~-7%/yr
-35%
1-yr DCF upside
+64%
-24%
5-yr DCF upside
+88%
-3%
10-yr DCF upside
+127%
The DCF is a cross-check on intrinsic value, separate from the quality-growth score above.
Model signals
ABBV
Why this score
- Raising its dividend
ANIP
No notable signals flagged.
The companies
ABBVAbbVie Inc.
Why now
Drug Manufacturers - General · market cap $467.4b. Trading near 52-week high of $267.47 — momentum setup, limited technical margin of safety. Revenue growing +10%, comfortably above the S&P median. PEG 0.43 — paying under fair value for the growth rate. 29 sell-side analysts rate this a Buy with a mean 1-yr target of $276.59 (implying +5% upside).
Moat
Free cash flow runs well ahead of reported net income — non-cash charges (depreciation, intangible amortization) are holding down GAAP earnings while cash generation stays strong. $467.4b market cap places it among the largest companies in the sector — distribution, R&D, and customer-acquisition costs amortize across a base peers can't replicate. Pharma moat is patent runway + pipeline depth — a single approved molecule funds the next generation of bets. Late-stage trials carry binary readouts that swing valuation 30%+.
Risk
Trailing P/E 74.5x prices in sustained high growth — any quarter that disappoints triggers sharp re-rating. Trading within 1% of the 52-week high — limited technical margin of safety; a momentum reversal would test conviction. ROE -106% is below the long-run sustainable threshold of ~10% — capital efficiency would need to improve for the equity base to compound at the market rate.
ANIPANI Pharmaceuticals, Inc.
Why now
Drug Manufacturers - Specialty & Generic · market cap $1.7b. Down 25% from 52-week high of $99.50 — deep drawdown territory. Revenue growing +31% — in hypergrowth territory. 8 sell-side analysts rate this a Buy with a mean 1-yr target of $108.38 (implying +46% upside).
Moat
ROE 18% sits above Buffett's preferred 15% threshold — the equity base is compounding at a rate the market struggles to discount accurately. FCF converts 160% of net income — earnings translate cleanly into cash, a sign that working capital and capex are well-disciplined. Pharma moat is patent runway + pipeline depth — a single approved molecule funds the next generation of bets. Late-stage trials carry binary readouts that swing valuation 30%+.
Risk
Trial-readout binary — late-stage clinical trials carry approve/reject outcomes that swing valuation 30%+; the equity is effectively a portfolio of these binary events, not a steady cash-flow business.
Verdict — model-derived comparison
Generating verdict… typically 5–10 seconds
Not investment advice. The Bull Rankings publishes a quantitative ranking model and accompanying analysis for general informational purposes only. Nothing on this page is a recommendation to buy, sell, or hold any security; nothing is personalized to your circumstances, risk tolerance, or tax situation. Investing carries the risk of loss — invest at your own risk and consider consulting a licensed financial professional before acting on anything you read here. See terms and methodology for full disclosures.
Where ABBV and ANIP diverge
On the headline score the gap is 16.4 points in favor of ANIP. They get there differently, though — each leads on a different pillar, so the better pick depends on which you weight.
- GrowthABBV 65.9 · ANIP 93.8ANIP +27.9
- ValueABBV 54.7 · ANIP 82.5ANIP +27.8
- QualityABBV 71.2 · ANIP 66.2ABBV +5.0
Pillars run 0–100 against sector peers, so a score is a statement about a company relative to its own industry rather than to the other name here. A wide Value gap usually means the market already prices the difference in quality or growth — which is the trade-off this comparison comes down to.